Leadership: Page 16
-
Making Moves
Making moves: Civica, Astellas, Inozyme and more announce key new hires
The latest hiring moves from Civica, Astella, Inozyme and the Flagship Pioneering-founded Tessera Therapeutics.
By Karissa Waddick • June 13, 2022 -
Q&A // First 90 Days
First 90 Days: Editas Medicine’s Gilmore O’Neill
The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.
By Michael Gibney • June 13, 2022 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Sponsored by ClinicalMind
4 steps to making data work for you
"Analytics" can sometimes feel like a four-letter word. Here are four steps to building a successful data-driven culture. No data science degree required.
June 13, 2022 -
Podcast
Woman of the Week: Janssen’s Najat Khan
Janssen’s Najat Khan, Ph.D., chief data science officer and global head of strategy and operations, shares how the company is using next-gen tech to ‘reimagine’ medicine.
By Taren Grom • June 8, 2022 -
As cancer innovations thrive, patient access is the next piece of the puzzle
Why enhanced clinical trials and diagnostics are keys to boosting patient access to cancer care.
By Michael Gibney • June 8, 2022 -
Profile
After losing her daughter to a rare disease, Sharon King is looking to rewrite the playbook of drug development
The communications pro is lending her community-building, storytelling expertise to the Bespoke Gene Therapy Consortium.
By Alexandra Pecci • June 7, 2022 -
Q&A // First 90 Days
First 90 Days: Janssen Immunology’s David Jimenez
The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.
By Taren Grom • June 6, 2022 -
How to build a cancer pipeline: Big Pharma oncology heads on driving science forward
Executives leading the cancer departments at J&J, Merck and Takeda chime in on what it takes to construct a successful and sustainable oncology drug pipeline.
By Michael Gibney • June 6, 2022 -
Profile
Flagship's creative approach to finding the next big idea in biopharma
Avak Kahvejian, partner at Flagship Pioneering, a company that conceives, creates and launches bioplatform companies like Moderna, discusses its latest venture, ProFound Therapeutics.
By Alexandra Pecci • June 1, 2022 -
Podcast
Woman of the Week: OcuTerra Therapeutics' Kerrie Brady
The serial entrepreneur and now head of OcuTerra explains why taking risks in pharma pays off.
By Taren Grom • June 1, 2022 -
Q&A // First 90 Days
First 90 Days: Sosei Heptares’ Chris Cargill
The company’s new CEO is looking to drive growth through collaboration and transparency.
By Kim Ribbink • May 31, 2022 -
PBMs under fire for drug prices defend their worth
A new Senate bill is putting PBMs in the crosshairs of lawmakers — but they argue that they're more than just middlemen.
By Michael Gibney • May 26, 2022 -
Making Moves
Making moves: Inovio, Veru, MindMed and more announce key new hires
The latest career moves in the biopharma industry from Veru, MindMed, Horizon Therapeutics and Inovio.
By Karissa Waddick • May 25, 2022 -
Q&A // First 90 Days
First 90 Days: Syneos Health’s Michelle Keefe
The newly minted CEO is leaning on her 30 years of experience leading high-performance teams to make her mark at Syneos.
By Taren Grom • May 23, 2022 -
Tracking trends in healthcare, from tech to patient care
High-performing leaders honored by the Healthcare Businesswomen’s Association share their views on the future of the industry.
By Taren Grom • May 20, 2022 -
Q&A
Ironwood Pharmaceuticals is charting a course to become a giant in GI
Ironwood’s CEO, Tom McCourt, discusses the company’s strategy for leveling up in the GI market.
By Karissa Waddick • May 19, 2022 -
Retrieved from Diego Camargo/PharmaVoice on May 17, 2022
Podcast
Woman of the Week: Sparrow Pharmaceuticals' Jamie MacPherson
The vice president of regulatory affairs and quality on embracing leadership challenges in drug development.
By Taren Grom • May 18, 2022 -
Profile
Jumping into pharma with big plans at a small company
SpringWorks Therapeutics' chief medical officer on the ambition that drives him and his company to develop treatments for cancer patients.
By Alexandra Pecci • May 17, 2022 -
Sophia Sharp-Donaldson, executive director, Global Strategic Sourcing and Procurement, Kite Pharma and one of this year's HBA Luminary honorees.
OpinionWhy 'soft' skills matter in the new era of leadership
Standout leaders honored by the Healthcare Businesswomen's Association discuss the rising value of the interpersonal approach.
By Taren Grom • May 12, 2022 -
Profile
With the shine of amyloid fading, tau is a rising star in Alzheimer's
The tau theory in Alzheimer's is being put to the test with phase 3 trial results due later this month from TauRx Pharmaceuticals.
By Michael Gibney • May 11, 2022 -
Podcast
Woman of the Week: AiCure's Michelle Marlborough
As chief product officer at AiCure, Michelle Marlborough is focused on solving tough patient challenges through technology.
By Taren Grom • May 11, 2022 -
Where hope and uncertainty meet: A cutting-edge cancer developer's winding road
Replimune is on the precipice of a new kind of cancer treatment, but its CEO knows something about ambiguity.
By Alexandra Pecci • May 9, 2022 -
Podcast
Woman of the Week: Amgen's Dr. Jane Parnes
As executive medical director, early development at Amgen, Dr. Jane Parnes has helped guide clinical research for upwards of 30 of the company’s investigational molecules, including the newly approved Tezspire for severe asthma — one of her career highlights.
By Taren Grom • May 4, 2022 -
Profile
Bayer executive makes strides toward a finish line for rare cancers
Bayer's SVP and general manager of U.S. oncology completed the Boston Marathon to honor his brother and bring attention to rare cancers.
By Alexandra Pecci • May 3, 2022 -
Q&A
One company's failed drug is this company's 'jewel'
Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.
By Meagan Parrish • May 2, 2022